Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Thioridazine
Drug ID BADD_D02200
Description A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
Indications and Usage For the treatment of schizophrenia and generalized anxiety disorder.
Marketing Status Discontinued; Prescription
ATC Code N05AC02
DrugBank ID DB00679
KEGG ID D00373
MeSH ID D013881
PubChem ID 5452
TTD Drug ID D0U1OE
NDC Product Code Not Available
Synonyms Thioridazine | Thioridazine Hydrochloride | Thioridazine HCL | Thioridazine-Neurazpharm | Thioridazine Neurazpharm | ThioridazineNeurazpharm | Thiozine | Aldazine | Meleril | Mellaril | Melleril | Melleryl | Melleretten | Melzine | Rideril | Sonapax | Apo-Thioridazine | Apo Thioridazine | ApoThioridazine
Chemical Information
Molecular Formula C21H26N2S2
CAS Registry Number 50-52-2
SMILES CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Seizures (incl subtypes)G protein-activated inward rectifier potassium channel 1P48549T3801210780978; 12684268; 9504382; 15150531
Sinus tachycardiaG protein-activated inward rectifier potassium channel 1P48549T3801210780978; 12684268; 9504382; 15150531
Tardive dyskinesiaD(2) dopamine receptorP14416T6716210821369; 10379516; 10893495; 9777180; 10889553
Tardive dyskinesiaD(3) dopamine receptorP35462T0255110821369; 10379516; 10893495; 9777180; 10889553
Tardive dyskinesiaD(4) dopamine receptorP21917T2498310821369; 10379516; 10893495; 9777180; 10889553
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.001--
Heart rate irregular13.14.04.003--Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hyperpyrexia08.05.02.002--Not Available
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Ileus paralytic07.02.05.001--Not Available
Incontinence07.01.06.011; 20.02.02.004; 17.05.01.006--Not Available
Jaundice23.03.03.030; 01.06.04.004; 09.01.01.004--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.003--
Leukopenia01.02.02.001--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Miosis17.02.11.002; 06.05.03.003--Not Available
Muscle rigidity15.05.04.001; 17.05.02.005--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.005--Not Available
Oculogyric crisis06.05.02.002; 17.01.03.002--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Opisthotonus17.01.03.005--Not Available
Pallor24.03.04.001; 08.01.03.032; 23.03.03.031--Not Available
Pancytopenia01.03.03.003--Not Available
Parkinsonism17.01.05.003--Not Available
Parotid gland enlargement07.06.03.001--Not Available
Photosensitivity reaction23.03.09.003--
Pregnancy test false positive13.10.05.003--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages